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Supplementary

Supplementary Figure 1: Generation of neoantigens by different mutation types
Different classes of mutations generate new peptide sequences (neoantigens) which may be presented on the tumour cells bound to MHC class I molecules. Sequence of 9 amino acids is shown with alterations relative to the wild type in red. Anchor residues in the peptide (usually positions 2 and 9) interact with MHC and when these are mutated they bind to MHC differentially compared to the wild type. Frameshift mutations create a novel peptide sequence which will differ at every residue and be highly distinct from the wild type sequence. RNAseq expression changes in mutated versus wildtype samples. The extent of NMD was estimated for all indel and SNV mutations by comparing the mRNA expression level in samples with a mutation to the median mRNA expression level of the same transcript across all other tumour samples where the mutation was absent.
Supplementary Figure 3: The impact of clonality of frameshift indels on CPI response
Non-synonymous SNV mutation burden (first), in-frame indel burden (second), frameshift indel burden (third) and clonal frameshift indel burden (fourth) are split by response to checkpoint inhibitor therapy in the Snyder et al., melanoma cohort. of Indels
